Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: A prospective randomised trial of 280 consecutive patients

Annals of Oncology

Volumn 12, Issue 5, 2001, Pages 647-653

  Hirsch, F R ^a,b   Osterlind K ^c,d   Jeppesen, N ^b   Dombernowsky, P ^c   Ingeberg, S ^d   Grundtvig Sorensen, P ^e   Kristensen, C ^a   Hansen, H H ^a  

^a Rigshospitalet   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d HILLERØD HOSPITAL   (Denmark)

^e ROSKILDE HOSPITAL   (Denmark)

Author keywords

Chemotherapy; High dose platin; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; HEMOGLOBIN; MESNA; TENIPOSIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 0034988286     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011132014518     Document Type: Article

References (48)

1. Incidence of lung cancer in Denmark
2. Management of small cell carcinoma of the lung
3. The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer. A randomized study of 288 consecutive patients
4. Current status of etoposide in the management of small-cell lung cancer
5. Long-term disease-free survival in small-cell carcinoma of the lung: A study of clinical determinants
6. Management of small cell lung cancer
7. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent
8. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis
9. Carboplatin-containing regimens for small cell lung cancer: Implications for management in the elderly
10. Pilot study of carboplatin (CBDCA) calculated by Egorin's formula plus oral etoposide (ETP) for elderly patients with small cell lung cancer (SCLC)
11. Oral etoposide and carboplatin: Effective therapy for elderly patients with small cell lung cancer
12. Randomized comparison of etoposide-cisplatin vs. etoposide carboplatin and irradiation in small-cell lung cancer: A Hellenic Co-operative Oncology Group study
13. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small cell lung cancer. A randomised trial with 5 years follow up
14. Intensive chemotherapy of small cell bronchogenic carcinoma
15. Treatment of extensive stage small cell bronchogenic carcinoma: Effects of variation in intensity of induction chemotherapy
16. A randomized comparison of high dose versus conventional dose cyclophosphamide, doxorubicin, and vincristine for extensive stage small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
17. High-dose cyclophosphamide in the induction therapy of small cell lung cancer: Minor improvements in rate of remission and survival
18. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer
19. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer
20. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer
21. Hematopoietic stem cell transplantation for small cell lung cancer
22. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant granulocyte macrophage colony-stimulating factor in extensive-stage small cell lung cancer: A multicenter randomized phase III study
23. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group
24. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Multicenter Randomized Trial
25. Determinants of improved outcome in small cell lung cancer: An analysis of the 2580-patient Southwest Oncology Group data base
26. Early death during chemotherapy in patients with small cell lung cancer. Derivation of a prognostic index for toxic death and progression
27. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma
28. Cisplatin-carboplatin therapy in extensive non-small cell lung cancer: A Cancer and Leukemia Group B study
29. Evaluation of cisplatin, carboplatin, and etoposide in metastatic non small cell lung cancercinoma
30. A phase II study of caboplatin cisplatin etoposide combination chemotherapy in advanced non-small-cell lung cancer
31. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer
32. Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer
33. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules
34. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group
35. Increasing dose intensity of cisplatin-etoposide in advanced non small cell lung carcinoma: A phase III randomized trial of the Spanish Lung Cancer Group
36. Increasing the dose intensity of chemotherapy by means of granulocyte-colony stimulating factor (G-CSF) support in the treatment of small cell lung cancer
37. High-dose chemotherapy: Is it standard management for any common solid tumor?
38. Epoetin alpha prevents anaemia and reduce transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer
39. Carboplatin dose-age: Prospective evaluation of a simple formula based on renal function
40. Combining cisplatin and carboplatin complementary or contradictory?
41. Overview of chemotherapy for small cell lung cancer
42. Teniposide and etoposide in previously untreated small-cell lung cancer: A randomized study
43. A meta-analysis of thoracic radiotherapy for small-cell lung cancer
44. Does thoracic irradiation improve survival and local control in limited-stage small cell carcinoma of the lung? A meta-analysis
45. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission
46. Extensive-disease small cell lung cancer: The thrill of victory, the agony of defeat
47. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma. A randomized study of 457 patients